A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

• Status: Terminated
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a proof of concept study, designed to look at the safety and antiviral activity of LCQ908 in hepatitis C infected patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Antiviral Agents

Criteria

Inclusion Criteria:

• Written informed consent.

• Male and female subjects 18 to 65 years of age with hepatitis C infections (genotypes 1, 2 or 3).

• No prior therapy or inadequate response to therapy for hepatitis C.

• Weight at least 50 kg and body mass index (BMI) within 18 - 35 kg/m2.

Exclusion Criteria:

• Use of other investigational drugs within at least 30 days of enrollment

• Women of child-bearing potential.

Other protocol-defined inclusion/exclusion criteria apply